Tacrolimus Intravenous and Uridine triacetate

• Generic Name: tacrolimus
• Dosage Forms: n.a.
• Other Brand Names: Astagraf XL, Envarsus XR, Prograf, Hecoria

Tacrolimus injection is used together with other medicines to prevent the body from rejecting a transplanted organ (eg, kidney, liver, or heart). Tacrolimus may be used with steroids, azathioprine, or mycophenolate mofetil. Tacrolimus belongs to a group of medicines known as immunosuppressive agents.

When a patient receives an organ transplant, the body's white blood cells will try to get rid of (reject) the transplanted organ. Tacrolimus works by suppressing the immune system to prevent the white blood cells from trying to get rid of the transplanted organ.

Tacrolimus is a very strong medicine. It can cause side effects that can be very serious, such as kidney problems. It may also decrease the body's ability to fight infections. You and your doctor should talk about the benefits of tacrolimus as well as the risks of using it.

Tacrolimus is to be given only by or under the direct supervision of a doctor.

• Generic Name: uridine
• Dosage Forms: n.a.
• Other Brand Names: Vistogard, Xuriden

This medication guide provides information about the Vistogard brand of uridine triacetate. Xuriden is another brand of uridine triacetate that is not covered in this medication guide.

Uridine triacetate works by slowing down cell damage caused by certain cancer medicines (capecitabine or fluorouracil).

Uridine triacetate is used to treat an overdose of capecitabine or fluorouracil.

Uridine triacetate is also used in an emergency to treat life-threatening side effects caused by capecitabine or fluorouracil. This includes effects on the heart, nervous system, stomach, intestines, or blood cells.

uridine triacetate may be given before overdose symptoms appear. However, treatment with uridine triacetate must begin within 96 hours after you last received capecitabine or fluorouracil.

Uridine triacetate may also be used for purposes not listed in this medication guide.